Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Migraine drug developer CoLucid nets $51.2mm in IPO

Executive Summary

CoLucid Pharmaceuticals Inc. (migraine) netted $51.2mm in its initial public offering of 5.5mm shares--slightly above the 5.36mm it planned--at $10, below its $13-15 range. Entities affiliated with the company's existing investors indicated they might buy $25mm in IPO shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies